Skip to main content

Advertisement

SpringerLink
Log in

Tissue gadolinium deposition in hepatorenally impaired rats exposed to Gd-EOB-DTPA: evaluation with inductively coupled plasma mass spectrometry (ICP-MS)

  • CONTRAST MEDIA
  • Published:
La radiologia medica Aims and scope Submit manuscript

Abstract

Purpose

This study was undertaken to quantify tissue gadolinium (Gd) deposition in hepatorenally impaired rats exposed to gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) by means of inductively coupled plasma mass spectrometry (ICP-MS) and to compare differences in Gd distribution among major organs as possible triggers for nephrogenic systemic fibrosis.

Materials and methods

Five hepatorenally impaired rats (5/6-nephrectomized, with carbon-tetrachloride-induced liver fibrosis) were injected with Gd-EOB-DTPA. Histological assessment was conducted and Gd content of the skin, liver, kidneys, lungs, heart, spleen, diaphragm, and femoral muscle was measured by inductively coupled plasma mass spectrometry (ICP-MS) at 7 days after last injection. In addition, five renally impaired rats were injected with Gd-EOB-DTPA and the degree of tissue Gd deposition was compared with that in the hepatorenally impaired rats.

Results

ICP-MS analysis revealed significantly higher Gd deposition in the kidneys, spleen, and liver (p = 0.009–0.047) in the hepatorenally impaired group (42.6 ± 20.1, 17.2 ± 6.1, 8.4 ± 3.2 μg/g, respectively) than in the renally impaired group (17.2 ± 7.7, 5.4 ± 2.1, 2.8 ± 0.7 μg/g, respectively); no significant difference was found for other organs. In the hepatorenally impaired group, Gd was predominantly deposited in the kidneys, followed by the spleen, liver, lungs, skin, heart, diaphragm, and femoral muscle. Histopathological investigation revealed hepatic fibrosis in the hepatorenally impaired group.

Conclusions

Compared with renally impaired rats, tissue Gd deposition in hepatorenally impaired rats exposed to Gd-EOB-DTPA was significantly increased in the kidneys, spleen, and liver, probably due to the impairment of the dual excretion pathways of the urinary and biliary systems.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cowper SE, Robin HS, Steinberg SM et al (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000–1001

    Article  CAS  PubMed  Google Scholar 

  2. Cowper SE, Su LD, Bhawan J et al (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23:383–393

    Article  CAS  PubMed  Google Scholar 

  3. Cowper SE (2003) Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 15:785–790

    Article  PubMed  Google Scholar 

  4. Thomsen HS (2004) Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol 14:1654–1656

    PubMed  Google Scholar 

  5. Schmook T, Budde K, Ulrich C et al (2005) Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant 20:220–222

    Article  PubMed  Google Scholar 

  6. DeHoratius DM, Cowper SE (2006) Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial 19:191–194

    Article  PubMed  Google Scholar 

  7. Perazella MA (2007) Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol 2:200–202

    Article  CAS  PubMed  Google Scholar 

  8. Perazella MA, Rodby RA (2007) Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial 20:179–185

    Article  PubMed  Google Scholar 

  9. Sadowski EA, Bennett LK, Chan MR et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148–157

    Article  PubMed  Google Scholar 

  10. Thomsen HS (2007) European Society of Urogenital Radiology guidelines on contrast media application. Curr Opin Urol 17:70–76

    Article  PubMed  Google Scholar 

  11. Kanal E, Broome DR, Martin DR et al (2008) Response to the FDA’s May 23, 2007, nephrogenic systemic fibrosis update. Radiology 246:11–14

    Article  PubMed  Google Scholar 

  12. Prince MR, Zhang H, Morris M et al (2008) Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 248:807–816

    Article  PubMed  Google Scholar 

  13. Wertman R, Altun E, Martin DR et al (2008) Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 248:799–806

    Article  PubMed  Google Scholar 

  14. Altun E, Martin DR, Wertman R et al (2009) Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy—report from two US universities. Radiology 253:689–696

    Article  PubMed  Google Scholar 

  15. Pietsch H, Lengsfeld P, Steger-Hartmann T et al (2009) Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 44:226–233

    Article  CAS  PubMed  Google Scholar 

  16. Proctor E, Chatamra K (1984) Standardized micronodular cirrhosis in the rat. Eur Surg Res 16:182–186

    Article  CAS  PubMed  Google Scholar 

  17. Knopp MV, Balzer T, Esser M et al (2006) Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 41:491–499

    Article  PubMed  Google Scholar 

  18. Bourrinet P, Martel E, El Amrani AI et al (2007) Cardiovascular safety of gadoterate meglumine (Gd-DOTA). Invest Radiol 42:63–77

    Article  CAS  PubMed  Google Scholar 

  19. Herborn CU, Honold E, Wolf M et al (2007) Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol 42:58–62

    Article  CAS  PubMed  Google Scholar 

  20. Runge VM (2001) Safety of magnetic resonance contrast media. Top Magn Reson Imaging 12:309–314

    Article  CAS  PubMed  Google Scholar 

  21. Sieber MA, Pietsch H, Walter J et al (2008) A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 43:65–75

    Article  PubMed  Google Scholar 

  22. Penfield JG, Reilly RF (2008) Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial 21:129–134

    Article  PubMed  Google Scholar 

  23. Leiner T, Kucharczyk W (2009) Special issue: nephrogenic systemic fibrosis. J Magn Reson Imaging 30:1233–1235

    Article  PubMed  Google Scholar 

  24. Thomsen HS (2009) Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am 47:827–831

    Article  PubMed  Google Scholar 

  25. Gschwend S, Ebert W, Schultze-Mosgau M et al (2011) Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol 46:556–566

    Article  CAS  PubMed  Google Scholar 

  26. Schuhmann-Giampieri G, Frenzel T, Schmitt-Willich H (1993) Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. Arzneimittelforschung 43:927–931

    CAS  PubMed  Google Scholar 

  27. Hamm B, Staks T, Muhler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792

    Article  CAS  PubMed  Google Scholar 

  28. Muhler A, Heinzelmann I, Weinmann HJ (1994) Elimination of gadolinium-ethoxybenzyl-DTPA in a rat model of severely impaired liver and kidney excretory function. An experimental study in rats. Invest Radiol 29:213–216

    Article  CAS  PubMed  Google Scholar 

  29. Sato T, Ito K, Tamada T et al (2013) Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS). Magn Reson Imaging 31:1412–1417

    Article  CAS  PubMed  Google Scholar 

  30. Caravan P, Ellison JJ, McMurry TJ et al (1999) Gadolinium (III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 99:2293–2352

    Article  CAS  PubMed  Google Scholar 

  31. Morcos SK (2007) Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Brit J Radiol 80:73–76

    Article  CAS  PubMed  Google Scholar 

  32. Morcos SK (2011) Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far? Eur Radiology 21:496–500

    Article  Google Scholar 

  33. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H et al (1991) A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 22:233-237; discussion 242

Download references

Conflict of interest

None of the authors have any conflicts of interest associated with this study. This study was supported by a Japan Society for the Promotion of Science Grant-in-Aid for Young Scientists (B) (Grant 23791458) and the Kawasaki Medical School Project (Grants 22-A37 and 23-61).

Author information

Authors and Affiliations

  1. Department of Radiology, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan

    Tomohiro Sato, Tsutomu Tamada, Shigeru Watanabe, Akihiko Kanki, Yasufumi Noda, Atsushi Higaki, Akira Yamamoto & Katsuyoshi Ito

  2. Department of Pathology, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan

    Hirotake Nishimura

Authors
  1. Tomohiro Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsutomu Tamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shigeru Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hirotake Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akihiko Kanki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasufumi Noda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Atsushi Higaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akira Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Katsuyoshi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomohiro Sato.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sato, T., Tamada, T., Watanabe, S. et al. Tissue gadolinium deposition in hepatorenally impaired rats exposed to Gd-EOB-DTPA: evaluation with inductively coupled plasma mass spectrometry (ICP-MS). Radiol med 120, 557–562 (2015). https://doi.org/10.1007/s11547-014-0492-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11547-014-0492-y

Keywords

Search

Navigation